Amyl Therapeutics, headquartered in Liège, Belgium, is developing a novel anti-amyloid protein therapeutic that binds to a common structural feature of amyloids, the cross-β amyloid fold ...
Amyloidosis develops from a bone marrow disorder. It occurs when an abnormal protein, called amyloid, builds up and forms deposits in the body. Amyloidosis is closely linked to MM. Amyloid light ...
The newest generation of Alzheimer's therapeutics targets accumulations of the protein amyloid beta with engineered antibodies, but the results have been underwhelming, with some adverse effects ...